Vascular device developer Conor Medsystems reported that the first patient has been enrolled in the company's CoStar II U.S. clinical trial.
The CoStar II trial (cobalt chromium stent with antiproliferative for restenosis) is designed to randomize approximately 1,700 patients at up to 75 U.S. sites and 15 international sites. The Menlo Park, CA-based firm expects the data from this trial to support its application for U.S. regulatory approval of its CoStar cobalt chromium paclitaxel-eluting stent.
By AuntMinnie.com staff writers
May 24, 2005
Related Reading
Conor Medsystems nets CE Mark, May 10, 2005
Conor Medsystems inks distribution deal, May 27, 2004
Conor Medsystems releases PISCES data, May 26, 2004
Conor Medsystems completes paclitaxel stent trial enrollment, March 25, 2004
Copyright © 2005 AuntMinnie.com
